The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...
SAN FRANCISCO — Rucaparib significantly improved radiographic PFS compared with physician’s choice of therapy for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed longer PFS with first-line osimertinib-chemotherapy than chemotherapy alone. OS data ...
NEWTON, Mass., Nov. 6, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of ...
Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback